...
首页> 外文期刊>癌と化学療法 >Advanced gastric cancer responding to pathological CR after neoadjuvant TS-1 combined with CDDP therapy--report of a case
【24h】

Advanced gastric cancer responding to pathological CR after neoadjuvant TS-1 combined with CDDP therapy--report of a case

机译:Neoadjuvant TS-1结合CDDP治疗后,晚期胃癌对病理CR进行响应 - 报告

获取原文
获取原文并翻译 | 示例

摘要

A 54-year-old woman with advanced gastric cancer was referred to our hospital. Because it was the yearend, we selected neoadjuvant TS-1 combined with CDDP therapy. TS-1 (60 mg bid) was administered orally for 21 consecutive days, and CDDP (60 mg/m(2)) was infused intravenously on day 8. One course was completed without serious toxicities. The primary tumor revealed partial response (PR) with no lymph node metastasis judged from barium meal study and upper GI endoscopic findings. After 3 weeks, a simple total gastrectomy with lymph node dissection was performed. The pathological diagnosis proved that there were no cancer cells in the primary lesion or regional lymph nodes, suggesting a complete response (CR) to chemotherapy. The postoperative course was uneventful, and she has been fine as an outpatient.
机译:一名54岁的女性患有先进的胃癌癌症被称为我们的医院。 因为它是常年,我们选择了Neoadjuvant TS-1结合CDDP疗法。 TS-1(60mg BID)连续21天口服给药,CDDP(60mg / m(2))在第8天静脉注入8.一切课程没有严重毒性。 原发性肿瘤揭示了部分反应(PR),没有淋巴结转移从钡餐研究和上GI内窥镜发现判断。 3周后,进行淋巴结剖面的简单胃切除术。 病理诊断证明,主要病变或区域淋巴结中没有癌细胞,表明化疗的完整反应(CR)。 术后课程是不行的,她一直很好作为门诊。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号